Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Cryptococcal Meningitis

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin-paclitaxel, with or without bevacizumab in patients with advanced cancer.

Journal for immunotherapy of cancer·2022

Same author

Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.

Nature communications·2020

Same author

Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.

Nature communications·2020

Same author

Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer.

JAMA oncology·2019

Same author

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.

JAMA oncology·2019

Same author

Telecytology implementation: Deployment of telecytology for rapid on-site evaluations at an Academic Medical Center.

Diagnostic cytopathology·2018

Search research articles

Related Experiment Video

Updated: Jun 22, 2026

An In Vitro Model for Studying Cellular Transformation by Kaposi Sarcoma Herpesvirus

An In Vitro Model for Studying Cellular Transformation by Kaposi Sarcoma Herpesvirus

Published on: August 25, 2017

Targeted therapy for Kaposi sarcoma.

Ryan J Sullivan¹, Liron Pantanowitz, Bruce J Dezube

¹Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy

|June 4, 2009

Summary

This summary is machine-generated.

Kaposi sarcoma (KS), a cancer linked to Kaposi sarcoma-associated herpesvirus (KSHV), often affects immunocompromised patients. Emerging therapies target KSHV replication and immune restoration for better KS treatment.

More Related Videos

Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus (KSHV)

Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus (KSHV)

Published on: September 14, 2010

Establishment and Quantification of De Novo Lytic Infection by Cell-free Kaposi's Sarcoma-Associated Herpesvirus

Establishment and Quantification of De Novo Lytic Infection by Cell-free Kaposi's Sarcoma-Associated Herpesvirus

Published on: August 15, 2025

Related Experiment Videos

Last Updated: Jun 22, 2026

An In Vitro Model for Studying Cellular Transformation by Kaposi Sarcoma Herpesvirus

An In Vitro Model for Studying Cellular Transformation by Kaposi Sarcoma Herpesvirus

Published on: August 25, 2017

Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus (KSHV)

Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus (KSHV)

Published on: September 14, 2010

Establishment and Quantification of De Novo Lytic Infection by Cell-free Kaposi's Sarcoma-Associated Herpesvirus

Establishment and Quantification of De Novo Lytic Infection by Cell-free Kaposi's Sarcoma-Associated Herpesvirus

Published on: August 15, 2025

Area of Science:

Oncology
Virology
Immunology

Background:

Kaposi sarcoma (KS) is caused by Kaposi sarcoma-associated herpesvirus (KSHV).
KS commonly affects individuals with immunodeficiency, such as those with HIV/AIDS or organ transplant recipients on immunosuppressants.
Current KS treatments offer short-term control with frequent recurrence.

Purpose of the Study:

To review emerging therapeutic targets for Kaposi sarcoma.
To highlight novel pathogenic mechanisms of KSHV infection relevant to KS treatment.
To discuss important clinicopathologic features of KS.

Main Methods:

Literature review of emerging KS therapies.
Analysis of novel KSHV pathogenic mechanisms.
Discussion of therapeutic targets including KSHV replication, immune restoration, and signal transduction pathways.

Main Results:

Novel therapeutic targets for KS have been identified based on KSHV's pathogenic mechanisms.
Key targets include inhibiting KSHV replication, restoring immune competence, and disrupting KSHV-utilized signal transduction pathways.
These emerging strategies aim to overcome limitations of traditional chemotherapy.

Conclusions:

New therapeutic strategies targeting KSHV and host immune responses show promise for improved KS management.
Understanding KSHV pathogenesis is crucial for developing effective treatments.
Further research into these novel targets could lead to more durable responses and improved outcomes for KS patients.